Cabozantinib for relapsed neuroblastoma: Single institution case series-Reference-Cited by-同舟云学术

Cabozantinib for relapsed neuroblastoma: Single institution case series

Published:2020-04-28 Issue:7 Volume:67 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Perisa Michael P.¹^ORCID,Storey Michael²,Streby Keri A.³⁴,Ranalli Mark A.³⁴,Skeens Micah³,Shah Nilay³⁴^ORCID

Affiliation:

1. Pediatric Residency Program Nationwide Children's Hospital Columbus Ohio

2. Department of Pharmacy Nationwide Children's Hospital Columbus Ohio

3. Division of Hematology/Oncology/Bone Marrow Transplant Nationwide Children's Hospital Columbus Ohio

4. Department of Pediatrics The Ohio State University College of Medicine Columbus Ohio

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.28317

Reference27 articles.

1. Neuroblastoma Origin and Therapeutic Targets for Immunotherapy

2. Neuroblastoma: clinical and biological approach to risk stratification and treatment

3. Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials

4. USFDA.Cometriq (cabozantinib) tablets full prescribing information;2012.https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf.

5. USFDA.Cabometyx (cabozantinib) tablets(2019). US prescribing information;2019.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208692s003lbl.pdf. Accessed April 10 2020.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Narrative review: precision medicine applications in neuroblastoma—current status and future prospects;Translational Pediatrics;2024-01

2. Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy;Biochemical Pharmacology;2023-10

3. The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents;Frontiers in Pediatrics;2022-08-10

4. Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma;Molecules;2021-11-23

5. Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models;Frontiers in Oncology;2021-10-13